Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ioline D. Henter, Rafael T. de Sousa, Philip W. Gold, Andre R. Brunoni, Carlos A. Zarate$suffix/text()$suffix/text() & Rodrigo Machado-Vieira. (2017) Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Review of Clinical Pharmacology 10:2, pages 153-166.
Read now
Read now
Miguel Reyes-Parada & Patricio Iturriaga-Vasquez. (2016) The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Expert Opinion on Drug Discovery 11:10, pages 969-981.
Read now
Read now
Articles from other publishers (31)
Liang Zhou & Jingjing Duan. (2023)
The role of
NMDARs
in the anesthetic and antidepressant effects of ketamine
. CNS Neuroscience & Therapeutics.
Crossref
Crossref
Alessandro Riccardi, Mario Guarino, Sossio Serra, Michele Spampinato, Simone Vanni, Dana Shiffer, Antonio Voza, Andrea Fabbri & Fabio De Iaco. (2023) Narrative Review: Low-Dose Ketamine for Pain Management. Journal of Clinical Medicine 12:9, pages 3256.
Crossref
Crossref
I Barrutieta-Arberas, N Ortuzar, A Vaquero-Rodríguez, M Picó-Gallardo, H Bengoetxea, MA Guevara, PA Gargiulo & JV Lafuente. (2023) The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus. Experimental Biology and Medicine 248:7, pages 588-595.
Crossref
Crossref
Songbai Xu, Xiaoxiao Yao, Bingjin Li, Ranji Cui, Cuilin Zhu, Yao Wang & Wei Yang. (2022) Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant. Frontiers in Pharmacology 12.
Crossref
Crossref
Michael Weiss & Werner Siegmund. (2021) Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged‐Release Ketamine With Emphasis on 2,6‐Hydroxynorketamines. Clinical Pharmacology in Drug Development 11:2, pages 194-206.
Crossref
Crossref
Yan Wei, Lijia Chang & Kenji Hashimoto. (2021) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Molecular Psychiatry 27:1, pages 559-573.
Crossref
Crossref
Chui C. Chong & Stephan A. Schug. (2021) Efficacy and Tolerability of Oral Compared with Sublingual Ketamine Lozenges as Rescue Analgesics in Adults for Acute Pain: The OSKet Trial. Clinical Drug Investigation 41:9, pages 817-823.
Crossref
Crossref
Eric S. Schwenk, Basant Pradhan, Rohit Nalamasu, Lucas Stolle, Irving W. Wainer, Michael Cirullo, Alexander Olson, Joseph V. Pergolizzi, Marc C. Torjman & Eugene R. Viscusi. (2021) Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity. Current Pain and Headache Reports 25:9.
Crossref
Crossref
Mahmoud Hasan, Christiane Modess, Tarek Roustom, Anne Dokter, Markus Grube, Andreas Link, Hélène Rey, Stefanie Adler, Konrad Meissner & Werner Siegmund. (2021) Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. Anesthesiology 135:2, pages 326-339.
Crossref
Crossref
Kai Zhang & Kenji Hashimoto. 2021. New Rapid-acting Antidepressants. New Rapid-acting Antidepressants
1
16
.
Ansgar Bokel, Ansgar Rühlmann, Michael C. Hutter & Vlada B. Urlacher. (2020)
Enzyme-Mediated Two-Step Regio- and Stereoselective Synthesis of Potential Rapid-Acting Antidepressant (2
S
,6
S
)-Hydroxynorketamine
. ACS Catalysis 10:7, pages 4151-4159.
Crossref
Crossref
Eric W. LumsdenTimothy A. TroppoliScott J. MyersPanos ZanosYasco AracavaJan KehrJacqueline LovettSukhan KimFu-Hua WangStaffan SchmidtCarleigh E. JennePeixiong YuanPatrick J. MorrisCraig J. ThomasCarlos A. ZarateJr.Jr., Ruin MoaddelStephen F. TraynelisEdna F. R. PereiraScott M. ThompsonEdson X. AlbuquerqueTodd D. Gould. (2019)
Antidepressant-relevant concentrations of the ketamine metabolite (2
R
,6
R
)-hydroxynorketamine do not block NMDA receptor function
. Proceedings of the National Academy of Sciences 116:11, pages 5160-5169.
Crossref
Crossref
Pan-Fen Wang, Alicia Neiner, Thomas R. Lane, Kimberley M. Zorn, Sean Ekins & Evan D. Kharasch. (2018) Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches. Molecular Pharmaceutics 16:2, pages 898-906.
Crossref
Crossref
Todd D. Gould, Carlos A. ZarateJr.Jr. & Scott M. Thompson. (2019) Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Annual Review of Pharmacology and Toxicology 59:1, pages 213-236.
Crossref
Crossref
Pan-Fen WangAlicia NeinerEvan D. Kharasch. (2018) Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase. Anesthesiology 129:4, pages 756-768.
Crossref
Crossref
Panos Zanos, Ruin Moaddel, Patrick J. Morris, Lace M. Riggs, Jaclyn N. Highland, Polymnia Georgiou, Edna F. R. Pereira, Edson X. Albuquerque, Craig J. Thomas, Carlos A. ZarateJr.Jr. & Todd D. Gould. (2018) Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews 70:3, pages 621-660.
Crossref
Crossref
Steven P. Cohen, Anuj Bhatia, Asokumar Buvanendran, Eric S. Schwenk, Ajay D. Wasan, Robert W. Hurley, Eugene R. Viscusi, Samer Narouze, Fred N. Davis, Elspeth C. Ritchie, Timothy R. Lubenow & William M. Hooten. (2018) Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Regional Anesthesia and Pain Medicine, pages 1.
Crossref
Crossref
Andréa T. Faccio, Francisco J. Ruperez, Nagendra S. Singh, Santiago Angulo, Marina F.M. Tavares, Michel Bernier, Coral Barbas & Irving W. Wainer. (2018) Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1862:6, pages 1505-1515.
Crossref
Crossref
P Zanos & T D Gould. (2018) Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry 23:4, pages 801-811.
Crossref
Crossref
Georg M. Fassauer, Robert Hofstetter, Mahmoud Hasan, Stefan Oswald, Christina Modeß, Werner Siegmund & Andreas Link. (2017) Ketamine metabolites with antidepressant effects: Fast, economical, and eco-friendly enantioselective separation based on supercritical-fluid chromatography (SFC) and single quadrupole MS detection. Journal of Pharmaceutical and Biomedical Analysis 146, pages 410-419.
Crossref
Crossref
Friederike A. Sandbaumhüter, Regula Theurillat & Wolfgang Thormann. (2017) Separation of hydroxynorketamine stereoisomers using capillary electrophoresis with sulfated β‐cyclodextrin and highly sulfated γ‐cyclodextrin. ELECTROPHORESIS 38:15, pages 1878-1885.
Crossref
Crossref
Rodrigo Machado-Vieira, Ioline D. Henter & Carlos A. Zarate Jr.. (2017) New targets for rapid antidepressant action. Progress in Neurobiology 152, pages 21-37.
Crossref
Crossref
Mahmoud Hasan, Robert Hofstetter, Georg M. Fassauer, Andreas Link, Werner Siegmund & Stefan Oswald. (2017) Quantitative chiral and achiral determination of ketamine and its metabolites by LC–MS/MS in human serum, urine and fecal samples. Journal of Pharmaceutical and Biomedical Analysis 139, pages 87-97.
Crossref
Crossref
Kennett D. Radford, Thomas Y. Park, Bong Hyo Lee, Sean Moran, Lisa A. Osborne & Kwang H. Choi. (2017) Dose-response characteristics of intravenous ketamine on dissociative stereotypy, locomotion, sensorimotor gating, and nociception in male Sprague-Dawley rats. Pharmacology Biochemistry and Behavior 153, pages 130-140.
Crossref
Crossref
Todd D Gould, Panos Zanos & Carlos A ZarateJrJr. (2016) Ketamine Mechanism of Action: Separating the Wheat from the Chaff. Neuropsychopharmacology 42:1, pages 368-369.
Crossref
Crossref
Friederike A. Sandbaumhüter, Regula Theurillat, Rima N. Bektas, Annette P.N. Kutter, Regula Bettschart-Wolfensberger & Wolfgang Thormann. (2016) Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis. Journal of Chromatography A 1467, pages 436-444.
Crossref
Crossref
Regula Theurillat, Friederike A. Sandbaumhüter, Regula Bettschart-Wolfensberger & Wolfgang Thormann. (2016) Microassay for ketamine and metabolites in plasma and serum based on enantioselective capillary electrophoresis with highly sulfated γ-cyclodextrin and electrokinetic analyte injection. ELECTROPHORESIS 37:9, pages 1129-1138.
Crossref
Crossref
Marie-Chantal Giroux, Raphael Santamaria, Pierre Hélie, Patrick Burns, Francis Beaudry & Pascal Vachon. (2016) Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesia. Experimental Animals 65:1, pages 63-75.
Crossref
Crossref
Shigeyuki Chaki & Kenichi Fukumoto. (2015) Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Pharmaceuticals 8:3, pages 590-606.
Crossref
Crossref
Sabrina R. Douglas, Botros B. Shenoda, Rehman A. Qureshi, Ahmet Sacan, Guillermo M. Alexander, Marielle Perreault, James E. Barrett, Enrique Aradillas-Lopez, Robert J. Schwartzman & Seena K. Ajit. (2015) Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome. The Journal of Pain 16:9, pages 814-824.
Crossref
Crossref
Lael Reinstatler & Nagy A. Youssef. (2015) Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature. Drugs in R&D 15:1, pages 37-43.
Crossref
Crossref